| 6.93 -0.26 (-3.62%) | 03-18 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 8.72 | 1-year : | 9.48 |
| Resists | First : | 7.47 | Second : | 8.11 |
| Pivot price | 7.28 |
|||
| Supports | First : | 6.42 | Second : | 5.34 |
| MAs | MA(5) : | 7.1 |
MA(20) : | 7.28 |
| MA(100) : | 8.64 |
MA(250) : | 10.47 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 29.4 |
D(3) : | 32.5 |
| RSI | RSI(14): 42.1 |
|||
| 52-week | High : | 17.44 | Low : | 6.4 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ACET ] has closed above bottom band by 4.9%. Bollinger Bands are 66.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 17 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 7.18 - 7.21 | 7.21 - 7.24 |
| Low: | 6.7 - 6.75 | 6.75 - 6.79 |
| Close: | 6.86 - 6.94 | 6.94 - 6.99 |
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Sun, 15 Mar 2026
Adicet Bio, Inc. (ACET) Competitors - Meyka
Sat, 14 Mar 2026
Clinical Trial Uncertainty Puts Adicet Bio’s Prula-cel Program and Financial Outlook at Risk - TipRanks
Fri, 13 Mar 2026
Guggenheim cuts Adicet Bio stock price target to $100 on valuation - Investing.com
Fri, 13 Mar 2026
ACET Stock Price, Quote & Chart | ADICET BIO INC (NASDAQ:ACET) - ChartMill
Thu, 12 Mar 2026
Adicet Bio 10-K: $0 Revenue, $(16.95) EPS on $(116.8M) Net Loss - TradingView
Thu, 12 Mar 2026
Adicet Bio (NASDAQ: ACET) outlines 2025 loss and cash runway into 2027 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 10 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 0.8 (%) |
| Held by Institutions | 69.8 (%) |
| Shares Short | 702 (K) |
| Shares Short P.Month | 691 (K) |
| EPS | -20 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 19.04 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -39.2 % |
| Return on Equity (ttm) | -71.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -11.93 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -98 (M) |
| Levered Free Cash Flow | -58 (M) |
| PE Ratio | -0.35 |
| PEG Ratio | 0 |
| Price to Book value | 0.36 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.68 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|